drugset / Trial / NCT00143130

Pregabalin In Partial Seizures Extension Study

NCT00143130

Phase 3 Completed 227 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

Timeline

Start
2005-04
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 150 mg
Subject Pregabalin Small molecule 600 mg

Indications